F-star Biotechnologische Forschungs- Und Entwicklungsges.m.b.h

Other

Greenovation Biotech Gmbh

F-star Therapeutics, Inc.

S-target Therapeutics Gmbh

Igeneon Krebs-immuntherapie Forschungs-und Entwicklungs-ag

Meridian Biopharmaceuticals Gmbh

Midatech Limited

Himmler, Gottfried

Altropus Gmbh

Gottfried Himmler

Florian Ruker

Geert Mudde

Gordana Wozniak-Knopp

Gerda Redl

Hans Loibner

Thomas Muster

Hermann W Katinger

Manfred Schuster

Franz J Steindl

Alexandra Trkola

Martin Purtscher

Anton Bauer

Georg Maiwald

Maximillian Woisetschlager

Manuela Loidl

Günter Waxenecker

Thomas Putz

Thomas William Rademacher

Michael Freissmuth

Soledad Penades Ullate

Rafael Ojeda Martinez De Castilla

Ralf Kircheis

Florian Rüker

Thomas Schlederer

Manuel Martin Lomas

Markus Klinger

Florian Rueker

Guenter Waxenecker

Africa Garcia Barrientes

Jose Luis De Paz Carrera

G C Mudde

Hesso Farhan

Helmut Eckert

Maximillian Woisetschlaeger

Hellmut Samonigg

Andreas Hauer

Eugen Stermetz

T Midatech Limited Rademacher

Maximilian Woisetschlaeger

Florian RÜCKER

Florian RÜKER

Geert C Mudde

The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of the immunoglobulin determining binding to an epitope of the cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to the epitope, its use and methods for producing it.

Multivalent immunoglobulins

Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.

Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.

Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies

The invention relates to a cytotoxic modular antibody with a molecular weight of up to 60 kD, specifically binding to a cell surface target with a binding affinity of Kd&#x3c;10M, a method of producing such antibody and its use as a therapeutic.

Cytotoxic immunoglobulin

The invention provides a method of producing an immune complex preparation based on a secretory immunoglobulin, which is non-human secretion derived, comprising providing an industrial scale production system, capable of producing an N-glycosylated Secretory Component, producing by such system a Secretory Component comprising at least 0.01 mol non-core fucose per mol Secretory Component, and combining said Secretory Component with at least one of IgA or IgM immunoglobulins having a native glycosylation pattern to obtain an immune complex. The invention provides an isolated recombinant Secretory Component comprising the amino acid sequence of SEQ ID 1, or a functionally active variant thereof, which has a Lewis-type N-glucosylation pattern and at least 2 mol non-core fucose per mol Secretory Component; and an immune complex preparation based on a secretory immunoglobulin, derived from sources other than human secretions, comprising a Secretory Component with a Lewis-type N-glucosylation pattern and at least 0.01 mol non-core fucose per mol Secretory Component, and at least one of IgA or IgM immunoglobulins having a native glycosylation pattern.

Secretory immunoglobulin complex

The present application relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.

Display of binding agents

A method for engineering an immunoglobulin having a variable domain and at least one modification in at least two structural loops of the immunoglobulin and determining the binding of the immunoglobulin to an epitope of an antigen, where the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of providing a nucleic acid encoding an immunoglobulin having at least two structural loops, modifying at least one nucleotide residue of each of the structural loops, transferring the modified nucleic acid in an expression system, expressing the modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether the modified immunoglobulin binds to the epitope.

Method for engineering immunoglobulins

Nanoparticles comprising adjuvants and antigens, such as tumor and pathogen antigens, are disclosed and their use in a range of applications such as for the treatment of cancer and infectious diseases. Immunogenic structures based on nanoparticles or antibodies with carbohydrate ligands, and their use for therapeutic and prophylactic purposes, and for the isolation and detection of antibodies directed against the carbohydrate structures.

Nanoparticles comprising antigens and adjuvants, and immunogenic structures

A method of engineering immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.

The present invention relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.

Growing community of inventors

Vienna, Austria

Gottfried Himmler